Health & Wellness

Press Releases

Atlantic Health System Announces Clinical Trial of Drug for Locally Advanced or Metastatic Pancreatic Cancer Patients

07c431ee75223e71db02_a07d2d57403ac43db2c4_Dr._Angela_Alistar_2017.jpg
Dr. Angela Alistar
07c431ee75223e71db02_a07d2d57403ac43db2c4_Dr._Angela_Alistar_2017.jpg

Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a Phase I clinical trial of CPI-613 in combination with chemotherapeutic agents, gemcitabine and nab-paclitaxel, for patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in collaboration with Atlantic Health System. CPI-613 is a first-in-class drug with a unique mode of action and is Rafael’s lead altered energy metabolism directed (AEMD) drug candidate. The drug is designed to disrupt the altered energy-production pathways in cancer cells by targeting their mitochondrial metabolism.

The primary aim of the study is to establish the maximum tolerated dose of CPI-613 when given in combination with gemcitabine/nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.

Secondary aims include:

Sign Up for E-News

(1) To describe the safety profile for the gemcitabine/nab-paclitaxel/CPI-613 combination.
(2) To determine the clinical activity of gemcitabine/nab-paclitaxel/CPI-613 in metastatic pancreatic cancer as measured by tumor response rate (RR) by RECIST criteria, progression-free survival (PFS), and overall survival (OS).

Encouraging results observed in earlier trials, including Phase I data from a trial led by Angela Alistar, MD that was recently published in The Lancet Oncology, demonstrated the preliminary efficacy of CPI-613 in combination with modified FOLFIRINOX (a multidrug treatment for advanced pancreatic cancer) in patients with metastatic pancreatic cancer. These results support further evaluation of CPI-613 in this indication.[1] The safety profile of CPI-613 in earlier trials, which shows the drug to be well tolerated, provides further support for evaluation of CPI-613 in combination with other drugs to maximize benefit.

In 2013, the MPACT study, a multinational, phase III clinical trial comparing gemcitabine/nab-paclitaxel to gemcitabine alone, demonstrated an improved median survival of 8.5 months as compared with 6.7 months for gemcitabine monotherapy (p=0.000015). While some clinical benefit was shown, these outcomes also highlight the need for new combination strategies to improve upon the outcomes seen with gemcitabine/nab-paclitaxel in the treatment of metastatic pancreatic cancer.

Dr. Alistar, medical director of GI Medical Oncology at the Carol G. Simon Cancer Center of Morristown Medical Center, Atlantic Health System, and the Principal Investigator for this trial, remarked, “Strategies to enhance our current standard of care options are sorely needed in pancreatic cancer. Due to the low toxicity profile of CPI -613 as a single agent, I anticipate good tolerance in combination with the gemcitabine/nab-paclitaxel regimen. I am excited to be able to offer this novel option to our patients with pancreatic cancer. Targeting metabolism in pancreatic cancer has a strong scientific rationale.”

Sanjeev Luther, Rafael Pharmaceuticals’ Chief Executive Officer, commented, “Our company’s motto of “One Patient at a Time” is especially relevant in this situation. Patients with a low tolerance for toxicity may not be eligible for the FOLFIRINOX combo. We believe that the gemcitabine/nab-paclitaxel regimen has the potential to be a potent treatment with less toxicity. It is especially meaningful for us to announce the initiation of this study on World Pancreatic Cancer Day.”

About Atlantic Health System

Atlantic Health System, headquartered in Morristown, N.J., is an integrated health care delivery system powered by a workforce of 16,000 team members dedicated to building healthier communities. The system is comprised of 350 sites of care, including six hospitals: Morristown Medical Center, Overlook Medical Center, Newton Medical Center, Chilton Medical Center, Hackettstown Medical Center and Goryeb Children’s Hospital. Atlantic Health System also supports communities through Atlantic Medical Group, Atlantic Rehabilitation, Atlantic Home Care and Hospice, and its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System sponsors the Atlantic Accountable Care Organization, one of the larger ACOs in the nation, and Optimus Healthcare Partners. 

 

About Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Reference

[1] Alistar A, Morris BB, Desnoyer R, et al. (2017). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. The Lancet Oncology. doi: 10.1016/S1470-2045(17)30314-5.

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Summit

Upcoming Events

Carousel_image_5842739aa0bf7254c392_what_stays_graphic

Sat, February 17, 8:00 PM

Dreamcatcher Repertory Theatre, Summit

What Stays by Laura Ekstrand and Jason Szamreta

Arts & Entertainment Community Calendar

Carousel_image_bc30a776270d0825eaac_what_stays_graphic

Sun, February 18, 2:00 PM

Dreamcatcher Repertory Theatre, Summit

What Stays by Laura Ekstrand and Jason Szamreta

Arts & Entertainment Community Calendar

Carousel_image_5ee8c2f0eb2fa7451dad_1936833_116854767125_491173_n

Sun, February 18, 3:00 PM

Lawton C. Johnson Summit Middle School, Summit

NJIO's Winter Concert

Arts & Entertainment

Summit Fire Department Blotter

12/16/17 7:42 am     FD dispatched to DE FOREST AVENUE and MAPLE STREET for a strong odor of natural gas in area. On arrival found an outside odor of natural gas. PSEG was requested and responded to the scene. Readings of 7% natural gas were found in the manholes in the center of the intersection. CVS was checked and zero readings for natural gas were found. Summit FD was released ...

Summit Police Blotter

February 12, 2018

2/1 - At 0955 hours a report was taken for a theft of a street sign. The unlawful incident occurred between an unknown time frame on Pine Grove Avenue. Value of the street sign was not immediately available at the time of the report.

2/5 - Roberto C. Noel-Berman, 23, of Summit was arrested and charged with possession of CDS. Mr. Noel-Berman was released with a pending court date.

2/5 - ...

Assistance Programs Available for JCP&L Customers to Help with Winter Heating Bills

February 16, 2018

As the cold weather continues, financial assistance programs are available for Jersey Central Power & Light (JCP&L) customers who need help with winter heating bills.

Assistance to qualifying JCP&L customers is available through the Lifeline, Universal Service Fund (USF), Weatherization, Payment Assistance for Gas and Electric (PAGE) and New Jersey SHARES programs.

Lifeline ...

Video: Point View's Deitze Tell CNBC Fed is 'On Track' for March Rate Hike

Point View Wealth Management's Founder, President and Chief Investment Strategist, David Dietze, live on CNBC on how to position your portfolio despite more volatility:

cnbc.com/video

For nearly 25 years, Point View Wealth Management, Inc. has been working with families in Summit and beyond, providing customized portfolio management services and comprehensive ...

Doing Well While Doing Good

The new tax law is predicted to reduce significantly the number of taxpayers who itemize deductions.  That has some concerned about charitable giving. There are ways for taxpayers who do not itemize deductions to give to charity and still receive some tax benefits.

Give from your IRA. Those aged 70-1/2 or older, who must take required minimum distributions from retirement accounts, can ...

AtlantiCast

AtlantiCast Medical Minute: Atlantic Orthopedic Institute’s Scoliosis and Spinal Deformity Center

On this episode of the AtlantiCast Medical Minute, we’ll take you inside the Atlantic Orthopedic Institute’s Scoliosis and Spinal Deformity Center, with the center’s director, Jason Lowenstein, MD.

Video Link: https://www.youtube.com/watch?v=1M7euCp86-c

Let the Games Begin

I am truly awed by the Olympics.  Watching these superb young athletes on TV inspires me to renew my membership to the gym and pursue my lifelong dream of taking home the gold.  

 

The problem is that in my deluded head, I can see actually see myself standing atop the podium.  I am wrapped in a puffy designer ski coat with a huge piece of bling slung around my neck ...

Movies! Movies! Movies! - Three Ways to Enjoy Movies

Most people who use the Summit Free Public Library are familiar with our video collection: thousands of DVDs and nearly 800 BluRays -- and growing!

In addition to recent box-office hits and Hollywood classics, we have foreign films, anime, and musical performances from Aida to ZZ Top. Binge-watch a must-see TV series, discover a new one, or introduce your kids to your childhood ...